Business

The CEO of Moderna rules out the effectiveness of his company’s vaccine against “Omicron”

The head of the pharmaceutical company “Moderna” said that it is unlikely that vaccines against Covid-19 will be effective against the mutated “Omicron” of the Corona virus, as was the case for the “Delta” strain.

The head of the pharmaceutical company “Moderna” said that it is unlikely that vaccines against Covid-19 will be effective against the mutated “Omicron” of the Corona virus, as was the case for the “Delta” strain.00:10 / 00:10AD

Speaking to the Financial Times, Stefan Bancel said: “I don’t think there is a world in which the efficiency is at the same level that we had with Delta .”

He added, “I think there will be a fundamental shortcoming. I don’t know how much it is because we need to wait for the data. But all the scientists I spoke to said that this wouldn’t be appropriate,” according to “Reuters

It is worth noting that ” Moderna ” had announced on Friday its intention to develop a booster dose of the vaccine intended to protect against the mutated “Omicron”.

As for Johnson & Johnson , it announced that it is “in the process of evaluating the effectiveness of its vaccine against Covid-19 against mutant mutants, including Omicron.”

The company added in a statement that it is simultaneously working on the production of “a vaccine that specifically targets Omicron, and will develop it as appropriate.”

The statement quoted Mathai Mamin, who is responsible for research at Johnson & Johnson’s “Janssen” company, which developed the vaccine against Covid-19, as saying that the company “remains confident” of the ability of its current single-dose vaccine to provide an immune response against various variables.

But Mamen stressed at the same time that Johnson & Johnson can “quickly” begin conducting clinical trials on the new version of the vaccine if necessary

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button